Setmelanotide

Label Rare disease

ClassMelanocortin-4 agonist

Typical routes in papersDaily SC on label

Half-life contextHours-range

EvidenceFDA-approved for rare genetic obesity

What it is

Setmelanotide (Imcivree) turns on the MC4 receptor that tells the brain “stop eating” in people whose leptin-POMC path is broken by specific genetic defects.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

On-label it can produce real weight change in those rare genotypes (POMC, PCSK1, LEPR, BBS).
It is not a general-population diet shot like Wegovy.
Skin darkening and sexual-arousal effects can appear because melanocortin receptors do more than hunger.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

MC4R agonism downstream of leptin/POMC; restores satiety signaling when that path is genetically interrupted.

Possible side effects / caveats

Hyperpigmentation, nausea, spontaneous erections / arousal, injection reactions. Wrong-patient use is the big conceptual error.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Label	Start 1–2 mg daily depending on age/indication; titrate	Daily SC	Rare-disease insert only

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.